Updated:
Alkermes plc
Alkermes plc is a neuroscience-focused biopharmaceutical company founded in 1987 and led by CEO Richard Pops.
Alkermes plc
Alkermes was founded in 1987 in Athlone, Ireland, initially focused on drug-delivery technologies. Richard Pops took over as CEO in 1991 and shifted the company toward proprietary CNS therapeutics, a pivot that would define its trajectory for three decades. The Pops family remains involved through board representation and shareholding, though Alkermes is a publicly traded corporation (NASDAQ: ALKS) rather than a closed family office. Alkermes focuses on central nervous system disorders, including addiction, schizophrenia, and major depressive disorder. Its commercial portfolio contains three approved products: Vivitrol (alcohol and opioid dependence), Aristada (schizophrenia), and Lybalvi (schizophrenia and bipolar I disorder). The company also maintains a mid-stage pipeline, including ALKS 2680 for narcolepsy, which began Phase 2 testing in 2023. Research and development spending exceeded $400 million in fiscal 2023 (per the firm's annual report, 2023). Operating from Dublin and Waltham, Mass., Alkermes markets products in the United States and out-licenses in select international territories. The company reported approximately $1.5 billion in total revenue for fiscal 2023, derived entirely from product sales and royalty income (per SEC filing, February 2024). Its professional headcount stands above 1,600, with significant operations in R&D, manufacturing (a facility in Wilmington, Ohio), and commercial sales. Alkermes also maintains a foundation, Alkermes Giving, which makes grants in mental health and addiction science. August 2024: Alkermes announced it would separate its oncology business into a new publicly traded company, Mural Oncology, effectively streamlining its focus to neuroscience (per the firm, August 2024). Alkermes is structurally distinct from a family office because it remains a public operating company with a market cap of roughly $6 billion as of mid-2024. The Pops family's wealth is tied to equity in the company, which trades daily and is subject to SEC disclosure requirements. This structure means capital-allocation decisions — R&D spend, M&A, share buybacks — are made by a public board and management team, not a single-family investment committee.
General information
Firm type
other
Year founded
1987
AUM
Undisclosed
Location
Region
Europe
Country
Ireland
City
Dublin
Corporate office
Dublin, Ireland
Additional offices
Waltham, Massachusetts, United States
Principals
Richard Pops
Chief Executive Officer
Iain Brown
Chief Financial Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Alkermes?
As a publicly traded corporation (NASDAQ: ALKS), Alkermes' capital-allocation decisions are made by its board of directors and executive management team, led by CEO Richard Pops and CFO Iain Brown. The board oversees R&D budget, M&A, and shareholder returns. The Pops family, as significant shareholders, influence direction through board representation.
Is Alkermes a family office or an operating company?
Alkermes is a commercial-stage biopharmaceutical operating company, not a family office. It generates revenue from product sales and has over 1,600 employees. The Pops family's wealth is concentrated in public equity of the company rather than a separate investment vehicle.
What therapeutic areas does Alkermes focus on?
Alkermes concentrates on central nervous system (CNS) disorders, specifically addiction, schizophrenia, major depressive disorder, and narcolepsy. Its commercial products include Vivitrol, Aristada, and Lybalvi. In August 2024, it spun off its oncology pipeline into Mural Oncology to focus exclusively on neuroscience.
Has Alkermes engaged in spin-offs or restructuring?
Yes. In August 2024, Alkermes spun off its early-stage oncology programs into a new public company, Mural Oncology (per the firm, August 2024). This followed a prior spin-off of its Akorn manufacturing business in 2019. These moves reflect a strategy to streamline R&D and unlock shareholder value.
Does the Pops family have philanthropic structures connected to Alkermes?
Alkermes operates a corporate foundation, Alkermes Giving, which awards grants in mental health and addiction science. The Pops family also likely maintains personal philanthropic vehicles, though details are not publicly reported.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: